Sant’Anna and others found that tolcapone, an FDA-approved molecule for Parkinson’s disease, inhibits TTR aggregation and toxicity, binds to TTR in human plasma, and stabilizes the tetramer dissociation in mice and humans (Sant’Anna et al., 2016). This evidence concerns the gene TTR and Parkinson disease.